4
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
200 recruiting
4
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Targovax Solutions AS, a subsidiary of Targovax ASA is a company with 4 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| malignant mesothelioma | Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102) | Des.TrialAppr. |
| malignant pancreatic neoplasm | 12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21) | Des.TrialAppr. |
| ovarian cancer | Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus | Des.TrialAppr. |
| soft tissue sarcoma | granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
49
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
49
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio